All News

Kawasaki.jpg

Diagnosis and Management of Kawasaki Disease

EurekAlert!

The journal Circulation has published a comprehensive overview called “Update on Diagnosis and Management of Kawasaki Disease,” summarizing data published since the 2017 American Heart Association Scientific Statement on Kawasaki Disease related to diagnostic criteria, risk scores and treatment options for children and adults with this condition.

Read Article
RheumNow Podcast square

Dr. Quotes (11.8.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week from RheumNow.com.

Read Article
RheumNow Podcast square

Blue Collar Arthritis (10.25.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.

Read Article
knee.injx_.ant_.jpg

SPRINGBOARD: Extended-release Intra-articular Corticosteroid Injection in Knee OA

Jack Cush, MD

A phase 2 trial of EP-104IAR (long-acting, fluticasone propionate) has shown 14 weeks of clinically meaningful pain relief in knee osteoarthritis (OA).

Read Article
vaccine.jpg

Inadequate Zoster Vaccination in Immunocompromised Patients

Jack Cush, MD

A VA study of shows that recombinant zoster vaccine (RZV) vaccination in immunocompromised patients or those receiving immunosuppressive medications is insufficient, given these are high risk individuals.

Read Article
guidelines.jpg (keep)

British Society Guidelines for Managing Behçet’s Disease

Jack Cush, MD

An exhaustive, full read guideline from the British Association of Dermatologists (BAD) and the British Society for Rheumatology (BSR) on the management and treatment of Behçet’s disease (BD) in 2024 has been published in Rheumatology.

Read Article
RheumNow Podcast square

I Can't Treat Ugly (9.20.2024)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and a new FDA approval for EGPA, this week on the Podcast.

Read Article
lupus SLE

Mycophenolate in New-Onset SLE

Jack Cush, MD

How aggressively do you treat newly diagnosed new-onset systemic lupus erythematosus (SLE), or should you wait for organ involvement?

Read Article

SELECT-GCA: Upa in GCA Merkel Upa 15 mg v 7.5 v PBO w slower GC taper 70% new onset, 30% relapse. Few prev on IL6 Primary endpt: sustained remission at w52- UPA 15 mg beats PBO (p=0.0019) 34% relapse in UPA vs 60% PBO Less steroids, longer time to flare @RheumNow #ACR24 #ACRBest https://t.co/1OV2889Ny0

Links:

Eric Dein ericdeinmd ( View Tweet)
Abatacept for GPA? Tx with Abacept did NOT significantly reduce rates of treatment failure compared to GC + PBO (background DMARD allowed) in non-severe, relapsing GPA Continued need for tx options in non-severe relapsing dz @RheumNow #ACR24 Abstract #0823 https://t.co/7GfprUzoL7

Links:

Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Literature review of the treatment of IgA Vasculitis (Henoch–Schönlein Purpura) suggests: - Glucocorticoids are 1st -line therapy, esp if severe - For minor HSP: colchicine, dapsone, & methotrexate may be useful - Also studied cyclosporine A, tacrolimus, MMF… https://t.co/ZoZX3kyHvo https://t.co/dS82ekuEkv
Dr. John Cush RheumNow ( View Tweet)
Susac syndrome is a rare disease of young women characterised by microvessel occlusive Dz limited to the brain, retina, and inner ear. Rx is steroids, but Lancet Rheumatol Review of Rx shows no benefit of immunosuppressive Rx https://t.co/FvJa9OZLWL https://t.co/NVS0I3ofm8

Links:

Dr. John Cush RheumNow ( View Tweet)
How would you treat an anti-synthetase overlap pt w/ myositis, polysynovitis & rapid ILD (pt on steroids)?

Dr. John Cush RheumNow ( View Tweet)

STAR study shows 102 RA pts in LDA > 3 mos & pred 5 mg/d did equally well with either prednisone taper or changing to hydrocortisone 20 mg/d and taperin HC. At 12 mos both wer able to D/C GC (55% HC vs 47% pred tapering; p=0.4). https://t.co/C6YTGiF0pN

Links:

Dr. John Cush RheumNow ( View Tweet)

SPRINGBOARD: Extended-release Intra-articular Corticosteroid Injection in Knee OA A phase 2 trial of EP-104IAR (long-acting, fluticasone propionate) has shown 14 weeks of clinically meaningful pain relief in knee osteoarthritis (OA). This intra-articular formulation is… https://t.co/IjlEDMmzzH https://t.co/Ly40yQgZ8e
Dr. John Cush RheumNow ( View Tweet)
Ganglion cysts are thin walled cavities contain a viscous, mucinous fluid, arising in proximity to joint capsules/tendon sheaths but do not communicate with the joint. Most common w/ repetitive strain or overuse, trauma, or inflam. arthritis. Steroid injx dont… https://t.co/nUlQvemYa5 https://t.co/gSNzBuPeW4
Dr. John Cush RheumNow ( View Tweet)
2 yr results from the PRAIRI study - 78 at-risk (for RA) pts Rx w/ placebo or 1000 mg IV RTX + I00 mg methylprednisolone (MP). While 1 yr result showed brief delay in RA development, at 2 yrs there was no benefit for QOL or RA development https://t.co/1CzEQn5zL4 https://t.co/Wvr2kWvDC5

Links:

Dr. John Cush RheumNow ( View Tweet)
Retrospective study compared IV methylprednisolone (IVMP) to oral glucocorticoids (GC) Rx in 419 #GCA pts (>90% vision Sx). 26% Rx w/ IVMP was not superior at survival or visual ac uity than GC, but IVMP was assoc w/ signif more diabetes @1 yr (OR 2.59) https://t.co/pRBA18Fzyw https://t.co/z6Sw5LTtGq

Links:

Dr. John Cush RheumNow ( View Tweet)
Trends in Early Undifferentiated PolyArthritis presentation. Over 3 eras (1998-2004-245 pts; 2005-10 266 pts; 2011-22 329 pts) many Sxs & Rx same. But Sxs duration 2.9 to 4.1mos, seropositivity 54 to 42%, Erosion score 18 to 9, mostly in Seroneg pts; Steroids incr 18 to 33%… https://t.co/AZfjqB4xGI https://t.co/GEwDWjccxl
Dr. John Cush RheumNow ( View Tweet)
Genentech announced top line results of the REGENCY Phase III study of obinutuzumab (Gazyva) in lupus nephritis. 271 LN (class III or IV; +/- V) taking MMF & steroids were given placebo or OBIN for 76 wks. OBIN was superior @ complete renal resp at 76 wks… https://t.co/Um9du7fgxE https://t.co/RRWumnbTuy
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×